Anti-inflammatory and cholesterol-reducing properties of apolipoprotein mimetics: A review

Journal of Lipid Research

Volumn 55, Issue 10, 2014, Pages 2007-2021

  White, C Roger ^a   Garber, David W ^b   Anantharamaiah, G M ^b,c  

^a University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Apolipoprotein A I; Apolipoprotein E; Atherosclerosis; High density lipoprotein; Inflammation; Low density lipoprotein; Mimetic peptides

Indexed keywords

4F PEPTIDE; ANTIINFLAMMATORY AGENT; APOLIPOPROTEIN A1 MIMETIC PEPTIDE; APOLIPOPROTEIN E MIMETIC PEPTIDE; APOLIPOPROTEIN MIMETIC PEPTIDE; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RECOMBINANT PROTEIN; TRIPEPTIDE; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BIOMIMETIC MATERIAL;

ANTIATHEROGENIC EFFECT; ANTIINFLAMMATORY ACTIVITY; ATHEROMA; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; CORONARY RISK; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LIPID METABOLISM; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; RISK REDUCTION; ANIMAL; BLOOD;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; BIOMIMETIC MATERIALS; CHOLESTEROL, HDL; CORONARY ARTERY DISEASE; HUMANS; HYPOLIPIDEMIC AGENTS;

EID: 84907482419     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.R051367     Document Type: Review

References (154)

1. Stone, N. J., J. G. Robinson, A. H. Lichtenstein, C. N. Bairey Merz, C. B. Blum, R. H. Eckel, A. C. Goldberg, D. Gordon, D. Levy, D. M. Lloyd-Jones, et al. 2014. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 129: S1-S45.
2. Josan, K., S. R. Majumdar, and F. A. McAlister. 2008. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ. 178: 576-584.
3. Voora, D., S. H. Shah, C. R. Reed, J. Zhai, D. R. Crosslin, C. Messer, B. A. Salisbury, and G. S. Ginsburg. 2008. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet. 1: 100-106.
4. Chen, Y., X. Z. Ruan, Q. Li, A. Huang, J. F. Moorhead, S. H. Powis, and Z. Varghese. 2007. Inflammatory cytokines disrupt LDL-receptor feedback regulation and cause statin resistance: a comparative study in human hepatic cells and mesangial cells. Am. J. Physiol. Renal Physiol. 293: F680-F687.
5. Melone, M., L. Wilsie, O. Palyha, A. Strack, and S. Rashid. 2012. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J. Am. Coll. Cardiol. 59: 1697-1705.
6. Campbell, C. Y., J. J. Rivera, and R. S. Blumenthal. 2007. Residual risk in statin-treated patients: future therapeutic options. Curr. Cardiol. Rep. 9: 499-505.
7. Fruchart, J. C., F. M. Sacks, M. P. Hermans, G. Assmann, W. V. Brown, R. Ceska, M. J. Chapman, P. M. Dodson, P. Fioretto, H. N. Ginsberg, et al.; Residual Risk Reduction Initiative (R3I). 2008. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Diab. Vasc. Dis. Res. 5: 319-335.
8. Gordon, T., W. B. Kannel, W. P. Castelli, and T. R. Dawber. 1981. Lipoproteins, cardiovascular disease, and death. The Framingham study. Arch. Intern. Med. 141: 1128-1131.
9. Castelli, W. P. 1988. Cholesterol and lipids in the risk of coronary heart disease: the Framingham Heart Study. Can. J. Cardiol. 4: 5A-10A.
10. Yvan-Charvet, L., N. Wang, and A. R. Tall. 2010. The role of HDL, ABCA1 and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler. Thromb. Vasc. Biol. 30: 139-143.
11. Lüscher, T. F., U. Landmesser, A. von Eckardstein, and A. M. Fogelman. 2014. High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target. Circ. Res. 114: 171-182.
12. Getz, G. S., and C. A. Reardon. 2009. Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall. J. Lipid Res. 50: S156-S161.
13. deGoma, E. M., R. L. deGoma, and D. J. Rader. 2008. Beyond high-density lipoprotein cholesterol levels. Evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J. Am. Coll. Cardiol. 51: 2199-2211.
14. Navab, M., G. M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, V. R. Grijalva, A. C. Wagner, J. S. Frank, G. Datta, D. Garber, et al. 2004. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 109: 3215-3220.
15. Belalcazar, L. M., and C. M. Ballantyne. 1998. Defining specific goals of therapy in treating dyslipidemia in the patient with low high-density lipoprotein cholesterol. Prog. Cardiovasc. Dis. 41: 151-174.
16. Gnasso, A., B. Lehner, W. Haberbosch, O. Leiss, K. von Bergmann, and J. Augustin. 1986. Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects. Metabolism. 35: 387-393.
17. Wierzbicki, A. S., D. P. Mikhailidis, R. Wray, M. Schacter, R. Cramb, W. G. Simpson, and C. B. Byrne. 2003. Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr. Med. Res. Opin. 19: 155-168.
18. Malik, S., and M. L. Kashyap. 2003. Niacin, lipids, and heart disease. Curr. Cardiol. Rep. 5: 470-476.
19. Maron, D. J., S. Fazio, and M. F. Linton. 2000. Current perspectives on statins. Circulation. 101: 207-213.
20. Chapman, M. J. 2004. Are the effects of statins on HDL-cholesterol clinically relevant? Eur. Heart J. 6: C58-C63.
21. Boden, W. E., J. L. Probstfield, T. Anderson, B. R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub; AIM-HIGH Investigators. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365: 2255-2267.
22. Landray, M. J., R. Haynes, J. C. Hopewell, S. Parish, T. Aung, J. Tomson, K. Wallendszus, M. Craig, L. Jiang, R. Collins, et al.; HPS2-THRIVE Collaborative Group. 2014. Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 371: 203-212.
23. Morehouse, L. A., E. D. Sugarman, P-A. Bourassa, T. M. Sand, F. Zimetti, F. Gao, G. H. Rothblat, and A. J. Milici. 2007. Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in NZW rabbits. J. Lipid Res. 48: 1263-1272.
24. Brousseau, M. E., E. J. Schaefer, M. L. Wolfe, L. T. Bloedon, A. G. Digenio, R. W. Clark, J. P. Mancuso, and D. J. Rader. 2004. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350: 1505-1515.
25. Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. C. Tardif, D. D. Waters, et al.; ILLUMINATE Investigators. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357: 2109-2122.
26. Schwartz, G. G., A. G. Olsson, M. Abt, C. M. Ballantyne, P. J. Barter, J. Brumm, B. R. Chaitman, I. M. Holme, D. Kallend, L. A. Leiter, et al.; dal-OUTCOMES Investigators. 2012. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N. Engl. J. Med. 367: 2089-2099.
27. Mohammadpour, A. H., and F. Akhlaghi. 2013. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective. Clin. Pharmacokinet. 52: 615-626.
28. Hirz, R., and A. M. Scanu. 1970. Reassembly in vitro of a serum high density lipoprotein. Biochim. Biophys. Acta. 207: 364-367.
29. Milanoapoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J. Clin. Invest. 66: 892-900.
30. Milanomobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization. Circulation. 103: 3047-3050.
31. Milano/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques. In vivo assessment by intravascular ultrasound and magnetic resonance imaging. J. Am. Coll. Cardiol. 51: 1098-1103.
32. Paris. exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry. 41: 2089-2096.
33. Chen, Z., E. A. O'Neill, R. D. Meurer, K. Gagen, S. Luell, S. P. Wang, M. Ichetovkin, B. Frantz-Wattley, S. Eveland, A. M. Strack, et al. 2012. Reconstituted HDL elicits marked changes in plasma lipids following single-dose injection in C57Bl/6 mice. J. Cardiovasc. Pharmacol. Ther. 17: 315-323.
34. Diditchenko, S., A. Gille, I. Pragst, D. Stadler, M. Waelchli, R. Hamilton, A. Leis, and S. D. Wright. 2013. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 33: 2202-2211.
35. Tardy, C., M. Goffinet, N. Boubekeur, R. Ackermann, G. Sy, A. Bluteau, G. Cholez, C. Keyserling, N. Lalwani, J. F. Paolini, et al. 2014. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice. Atherosclerosis. 232: 110-118.
36. Eriksson, M., L. A. Carlson, T. A. Miettinen, and B. Angelin. 1999. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 100: 594-598.
37. Waksman, R., R. Torguson, K. M. Kent, A. D. Pichard, W. O. Suddath, L. F. Satler, B. D. Martin, T. J. Perlman, J. A. Maltais, N. J. Weissman, et al. 2010. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J. Am. Coll. Cardiol. 55: 2727-2735.
38. Tardif, J. C., C. M. Ballantyne, P. Barter, J. L. Dasseux, Z. A. Fayad, M. C. Guertin, J. J. P. Kastelein, C. Keyserling, H. Klepp, W. Koenig, et al.; for the Can HDL Infusions Significantly Quicken Atherosclerosis Regression (CHI-SQUARE) Investigators. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur. Heart J. Epub ahead of print. April 29, 2014; doi:10.1093/eurheartj/ehu171.
39. Tardif, J. C., J. Grégoire, P. L. L'Allier, R. Ibrahim, J. Lespérance, T. M. Heinonen, S. Kouz, C. Berry, R. Basser, M. A. Lavoie, et al.; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. 2007. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA. 297: 1675-1682.
40. Gille, A., S. Wright, R. Easton, and C. Shear. 2013. Infusion of CSL112, a novel formulation of human apolipoprotein A-I, in healthy subjects removes tissue cholesterol and directs its clearance. Eur. Heart J. 34(suppl 1): 10.1093/eurheartj/eht308.1947.
41. Easton, R., A. Gille, D. D'Andrea, R. Davis, S. D. Wright, and C. Shear. 2014. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I. J. Clin. Pharmacol. 54: 301-310.
42. Milano-apoA-II supports its peculiar susceptibility to proteolysis. Biophys. J. 91: 3043-3049.
43. Gong, E. L., L. J. Stoltzfus, C. M. Brion, D. Murugesh, and E. M. Rubin. 1996. Contrasting in vivo effects of murine and human apolipoprotein A-II: role of monomer versus dimer. J. Biol. Chem. 271: 5984-5987.
44. Escolà-Gil, J. C., À. Marzal-Casacuberta, J. Julve-Gil, B. Y. Ishida, J. Ordóñez-Llanos, L. Chan, F. Gonzãlez-Sastre, and F. Blanco-Vaca. 1998. Human apolipoprotein A-II is a pro-atherogenic molecule when it is expressed in transgenic mice at a level similar to that in humans: evidence of a potentially relevant species-specific interaction with diet. J. Lipid Res. 39: 457-462.
45. Yi, D. W., D. W. Jeong, S. Y. Lee, S. M. Son, and Y. H. Kang. 2012. The association between apolipoprotein A-II and metabolic syndrome in Korean adults: a comparison study of apolipoprotein A-I and apolipoprotein B. Diabetes Metab. J. 36: 56-63.
46. Nissen, S. E., T. Tsunoda, E. M. Tuzcu, P. Schoenhagen, C. J. Cooper, M. Yasin, G. M. Eaton, M. A. Lauer, W. S. Sheldon, C. L. Grines, et al. 2003. Effect of recombinant apoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 290: 2292-2300.
47. Chung, B. H., G. M. Anatharamaiah, C. G. Brouillette, T. Nishida, and J. P. Segrest. 1985. Studies of synthetic peptide analogs of the amphipathic helix. Correlation of structure with function. J. Biol. Chem. 260: 10256-10262.
48. Segrest, J. P., R. L. Jackson, J. D. Morrisett, and A. M. Gotto, Jr. 1974. A molecular theory of lipid-protein interactions in the plasma lipoproteins. FEBS Lett. 38: 247-258.
49. Segrest, J. P., D. W. Garber, C. G. Brouillette, S. C. Harvey, and G. M. Anantharamaiah. 1994. The amphipathic α helix: A multifunctional structural motif in plasma apolipoproteins. Adv. Protein Chem. 45: 303-369.
50. Yokoyama, S., D. Fukushima, J. P. Kupferberg, F. J. Kézdy, and E. T. Kaiser. 1980. The mechanism of activation of lecithin:cholesterol acyltransferase by apolipoprotein A-I and an amphiphilic peptide. J. Biol. Chem. 255: 7333-7339.
51. Ponsin, G., K. Strong, A. M. Gotto, Jr., J. T. Sparrow, and H. J. Pownall. 1984. In vitro binding of synthetic acylated lipid-associating peptides to high-density lipoproteins: effect of hydrophobicity. Biochemistry. 23: 5337-5342.
52. Anantharamaiah, G. M., J. L. Jones, C. G. Brouillette, C. F. Schmidt, B. H. Chung, T. A. Hughes, A. S. Bhown, and J. P. Segrest. 1985. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J. Biol. Chem. 260: 10248-10255.
53. Mendez, A. J., G. M. Anantharamaiah, J. P. Segrest, and J. F. Oram. 1994. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J. Clin. Invest. 94: 1698-1705.
54. Epand, R. M., A. Gawish, M. Iqbal, K. B. Gupta, C. H. Chen, J. P. Segrest, and G. M. Anantharamaiah. 1987. Studies of synthetic peptide analogs of the amphipathic helix. Effect of charge distribution, hydrophobicity, and secondary structure on lipid association and lecithin:cholesterol acyltransferase activation. J. Biol. Chem. 262: 9389-9396.
55. Tang, C., A. M. Vaughan, G. M. Anantharamaiah, and J. F. Oram. 2006. Janus kinase 2 modulates the lipid-removing but not proteinstabilizing interactions of amphipathic helices with ABCA1. J. Lipid Res. 47: 107-114.
56. Datta, G., M. Chaddha, S. Hama, M. Navab, A. M. Fogelman, D. W. Garber, V. K. Mishra, R. M. Epand, R. F. Epand, S. Lund-Katz, et al. 2001. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J. Lipid Res. 42: 1096-1104.
57. Jonas, A. 1986. Reconstitution of high-density lipoproteins. Methods Enzymol. 128: 553-582.
58. Garber, D. W., G. Datta, M. Chaddha, M. N. Palgunachari, S. Y. Hama, M. Navab, A. M. Fogelman, J. P. Segrest, and G. M. Anantharamaiah. 2001. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J. Lipid Res. 42: 545-552.
59. Anantharamaiah, G. M., Y. V. Venkatachalapathi, C. G. Brouillette, and J. P. Segrest. 1990. Use of synthetic peptide analogues to localize lecithin:cholesterol acyltransferase activating domain in apolipoprotein A-I. Arteriosclerosis. 10: 95-105.
60. Navab, M., G. M. Anantharamaiah, S. T. Reddy, S. Hama, G. Hough, J. S. Frank, V. R. Grijalva, V. K. Ganesh, V. K. Mishra, M. N. Palgunachari, et al. 2005. Oral small peptides render HDL antiinfl ammatory in mice and monkeys and reduce atherosclerosis in ApoE null mice. Circ. Res. 97: 524-532.
61. Navab, M., G. M. Anantharamaiah, S. T. Reddy, B. J. Van Lenten, A. C. Wagner, S. Hama, G. Hough, E. Bachini, D. W. Garber, V. K. Mishra, et al. 2005. An oral apoJ peptide renders HDL antiinflammatory in mice and monkeys and dramatically reduces atherosclerosis in apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 25: 1932-1937.
62. Wool, G. D., T. Vaisar, C. A. Reardon, and G. S. Getz. 2009. An apoA-I mimetic peptide containing a proline residue has greater in vivo HDL binding and anti-inflammatory ability than the 4F peptide. J. Lipid Res. 50: 1889-1900.
63. Remaley, A. T., F. Thomas, J. A. Stonik, S. J. Demosky, S. E. Bark, E. B. Neufeld, A. V. Bocharov, T. G. Vishnyakova, A. P. Patterson, T. L. Eggerman, et al. 2003. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J. Lipid Res. 44: 828-836.
64. Ditiatkovski, M., W. D'Souza, R. Kesani, J. Chin-Dusting, J. B. de Haan, A. Remaley, and D. Sviridov. 2013. An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice. PLoS ONE. 8: e68802.
65. Bielicki, J. K., H. Zhang, Y. Cortez, Y. Zheng, V. Narayanaswami, A. Patel, J. Johansson, and S. Azhar. 2010. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice. J. Lipid Res. 51: 1496-1503.
66. Zhao, Y., T. Imura, L. J. Leman, L. K. Curtiss, B. E. Maryanoff, and M. R. Ghadiri. 2013. Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs. J. Am. Chem. Soc. 135: 13414-13424.
67. Palgunachari, M. N., V. K. Mishra, S. Lund-Katz, M. C. Phillips, S. O. Adeyeye, S. Alluri, G. M. Anantharamaiah, and J. P. Segrest. 1996. Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity. Implications for HDL assembly. Arterioscler. Thromb. Vasc. Biol. 16: 328-338.
68. Van Lenten, B. J., A. C. Wagner, C. L. Jung, P. Ruchala, A. J. Waring, R. I. Lehrer, A. D. Watson, S. Hama, M. Navab, G. M. Anantharamaiah, et al. 2008. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I. J. Lipid Res. 49: 2302-2311.
69. Ou, J., Z. Ou, D. W. Jones, S. Holzhauer, O. A. Hatoum, A. W. Ackerman, D. W. Weihrauch, D. D. Gutterman, K. Guice, K. T. Oldham, et al. 2003. L-4F, an apolipoprotein A-1 mimetic, dramatically improves vasodilation in hypercholesterolemia and sickle cell disease. Circulation. 107: 2337-2341.
70. Peterson, S. J., G. Drummond, D. H. Kim, M. Li, A. L. Kruger, S. Ikehara, and N. G. Abraham. 2008. L-4F treatment reduces adiposity, increases adiponectin levels, and improves insulin sensitivity in obese mice. J. Lipid Res. 49: 1658-1669.
71. Vecoli, C., J. Cao, D. Neglia, K. Inoue, K. Sodhi, L. Vanella, K. K. Gabrielson, D. Bedja, N. Paolocci, A. L'abbate, et al. 2011. Apolipoprotein A-I mimetic peptide L-4F prevents myocardial and coronary dysfunction in diabetic mice. J. Cell. Biochem. 112: 2616-2626.
72. Morgantini, C., S. Imaizumi, V. Grijalva, M. Navab, A. M. Fogelman, and S. T. Reddy. 2010. Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes. Diabetes. 59: 3223-3228.
73. Xie, Q., S. P. Zhao, and F. Li. 2010. D-4F, an apolipoprotein A-I mimetic peptide, promotes cholesterol efflux from macrophages via ATP-binding cassette transporter A1. Tohoku J. Exp. Med. 220: 223-228.
74. Garber, D. W., Y. V. Venkatachalapathi, K. B. Gupta, J. Ibdah, M. C. Phillips, J. B. Hazelrig, J. P. Segrest, and G. M. Anantharamaiah. 1992. Turnover of synthetic class A amphipathic peptide analogues of exchangeable apolipoproteins in rats. Correlation with physical properties. Arterioscler. Thromb. 12: 886-894.
75. Navab, M., G. M. Anantharamaiah, S. Hama, D. W. Garber, M. Chaddha, G. Hough, R. Lallone, and A. M. Fogelman. 2002. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 105: 290-292.
76. Van Lenten, B. J., A. C. Wagner, M. Navab, G. M. Anantharamaiah, S. Hama, S. T. Reddy, and A. M. Fogelman. 2007. Lipoprotein inflammatory properties and serum amyloid A levels but not cholesterol levels predict lesion area in cholesterol-fed rabbits. J. Lipid Res. 48: 2344-2353.
77. Ansell, B. J., M. Navab, S. Hama, N. Kamranpour, G. Fonarow, G. Hough, S. Rahmani, R. Mottahedeh, R. Dave, S. T. Srinivasa, et al. 2003. Inflammatory/anti-inflammatory properties of high density lipoprotein distinguish patients from control subjects better than high density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 108: 2751-2756.
78. Wool, G. D., V. G. Cabana, J. Lukens, P. X. Shaw, C. J. Binder, J. L. Witztum, C. A. Reardon, and G. S. Getz. 2011. 4F Peptide reduces nascent atherosclerosis and induces natural antibody production in apolipoprotein E-null mice. FASEB J. 25: 290-300.
79. Navab, M., G. M. Anantharamaiah, S. Hama, G. Hough, S. T. Reddy, J. S. Frank, D. W. Garber, S. Handattu, and A. M. Fogelman. 2005. D-4F and statins synergize to render HDL anti-inflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 25: 1426-1432.
80. Navab, M., S. T. Reddy, G. M. Anantharamaiah, S. Imaizumi, G. Hough, S. Hama, and A. M. Fogelman. 2011. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J. Lipid Res. 52: 1200-1210.
81. Chattopadhyay, A., M. Navab, G. Hough, F. Gao, D. Meriwether, V. Grijalva, J. R. Springstead, M. N. Palgnachari, R. Namiri-Kalantari, F. Su, et al. 2013. A novel approach to oral apoA-I mimetic therapy. J. Lipid Res. 54: 995-1010. [Erratum. 2013. J. Lipid Res. 54: 3220.]
82. Navab, M., G. Hough, G. M. Buga, F. Su, A. C. Wagner, D. Meriwether, A. Chattopadhyay, F. Gao, V. Grijalva, J. S. Danciger, et al. 2013. Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. J. Lipid Res. 54: 3403-3418.
83. Gomaraschi, M., L. Calabresi, G. Rossoni, S. Iametti, G. Franceschini, J. A. Stonik, and A. T. Remaley. 2008. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. J. Pharmacol. Exp. Ther. 324: 776-783.
84. Sethi, A. A., J. A. Stonik, F. Thomas, S. J. Demosky, M. Amar, E. Neufeld, H. B. Brewer, W. S. Davidson, W. D'Souza, D. Sviridov, et al. 2008. Asymmetry in the lipid affinity of bihelical amphipathic peptides. A structural determinant for the specificity of ABCA1-dependent cholesterol efflux by peptides. J. Biol. Chem. 283: 32273-32282.
85. Tabet, F., A. T. Remaley, A. I. Segaliny, J. Millet, L. Yan, S. Nakhla, P. J. Barter, K. A. Rye, and G. Lambert. 2010. The 5A apolipoprotein A-I mimetic peptide displays antiinflammatory and antioxidant properties in vivo and in vitro. Arterioscler. Thromb. Vasc. Biol. 30: 246-252.
86. Yao, X., C. Dai, K. Fredriksson, P. K. Dagur, J. P. McCoy, X. Qu, Z. X. Yu, K. J. Keeran, G. J. Zywicke, M. J. Amar, et al. 2011. 5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma. J. Immunol. 186: 576-583.
87. D'Souza, W., J. A. Stonik, A. Murphy, S. J. Demosky, A. A. Sethi, X. L. Moore, J. Chin-Dusting, A. T. Remaley, and D. Sviridov. 2010. Structure/function relationships of apolipoprotein A-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein. Circ. Res. 107: 217-227.
88. Mishra, V. K., M. N. Palgunachari, S. Lund-Katz, M. C. Phillips, J. P. Segrest, and G. M. Anantharamaiah. 1995. Effect of the arrangement of tandem repeating units of class A amphipathic alpha-helixes on lipid interaction. J. Biol. Chem. 270: 1602-1611.
89. Zhao, Y., A. S. Black, D. J. Bonnet, B. E. Maryanoff, L. K. Curtiss, L. J. Leman, and M.R. Ghadiri. In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I. J. Lipid Res. Epub ahead of print. June 29, 2014; doi:10.1194/jlr.M049262.
90. Bloedon, L. T., R. Dunbar, D. Duffy, P. Pinell-Salles, R. Norris, B. J. DeGroot, R. Movva, M. Navab, A. M. Fogelman, and D. J. Rader. 2008. Safety, pharmacokinetics and pharmacodynamics of a single dose of oral apolipoprotein A-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 49: 1344-1352.
91. Watson, C. E., N. Weissbach, L. Kjems, S. Ayalasomayajula, Y. Zhang, I. Chang, M. Navab, S. Hama, G. Hough, S. T. Reddy, et al. 2011. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J. Lipid Res. 52: 361-373.
92. Reddy, S. T., M. Navab, G. M. Anantharamaiah, and A. M. Fogelman. 2014. Searching for a successful HDL-based treatment strategy. Biochim. Biophys. Acta. 1841: 162-167.
93. Datta, G., M. Chaddha, D. W. Garber, B. H. Chung, E. M. Tytler, N. Dashti, W. A. Bradley, S. H. Gianturco, and G. M. Anantharamaiah. 2000. The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry. 39: 213-220.
94. Segall, M. L., P. Dhanasekaran, F. Baldwin, G. M. Anantharamaiah, K. H. Weisgraber, M. C. Phillips, and S. Lund-Katz. 2002. Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization. J. Lipid Res. 43: 1688-1700.
95. Gonzales, J. C., P. L. Gordts, E. M. Foley, and J. D. Esko. 2013. Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans. J. Clin. Invest. 123: 2742-2751.
96. Zhu, Y., S. Bellosta, C. Langer, F. Bernini, R. E. Pitas, R. W. Mahley, G. Assmann, and A. von Eckardstein. 1998. Low-dose expression of a human apolipoprotein E transgene in macrophages restores cholesterol efflux capacity of apolipoprotein E-deficient mouse plasma. Proc. Natl. Acad. Sci. USA. 95: 7585-7590.
97. Linton, M. F., J. B. Atkinson, and S. Fazio. 1995. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 267: 1034-1037.
98. Davignon, J. 2005. Apolipoprotein E and atherosclerosis-beyond lipid effect. Arterioscler. Thromb. Vasc. Biol. 25: 267-269.
99. Gaudreault, N., N. Kumar, J. M. Posada, K. B. Stephens, N. S. Reyes de Mochel, D. Eberle, V. R. Olivas, R. Y. Kim, M. J. Harms, S. Johnson, et al. 2012. ApoE suppresses atherosclerosis by reducing lipid accumulation in circulating monocytes and the expression of inflammatory monocytes on monocytes and vascular endothelium. Arterioscler. Thromb. Vasc. Biol. 32: 264-272.
100. Ali, K., M. Middleton, E. Pure, and D. J. Rader. 2005. Apolipoprotein E suppresses the type I inflammatory response in vivo. Circ. Res. 97: 922-927.
101. Van Oosten, M., P. C. N. Rensen, E. S. Van Amersfoort, M. Van Eck, A. M. Van Dami, J. J. P. Breve, T. Vogel, A. Panet, T. J. C. Van Berkel, and J. Kuiper. 2001. Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. J. Biol. Chem. 276: 8820-8824.
102. de Bont, N., M. G. Netea, P. N. M. Demacker, B. J. Kullberg, J. W. van der Meer, and A. F. Stalenhoef. 2000. Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. Eur. J. Clin. Invest. 30: 818-822.
103. Wang, H., D. J. Christensen, M. P. Vitek, P. M. Sullivan, and D. T. Laskowitz. 2009. APOE genotype affects outcome in a murine model of sepsis: implications for a new treatment strategy. Anaesth. Intensive Care. 37: 38-45.
104. Moretti, E. W., R. W. Morris, M. Podgoreanu, D. A. Schwinn, M. F. Newman, E. Bennett, V. G. Moulin, U. U. Mba, and D. T. Laskowitz. 2005. APOE polymorphism is associated with risk of severe sepsis in surgical patients. Crit. Care Med. 33: 2521-2526.
105. Roselaar, S. E., and A. Daugherty. 1998. Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. J. Lipid Res. 39: 1740-1743.
106. Levine, D. M., T. S. Parker, T. M. Donnelly, A. Walsh, and A. L. Rubin. 1993. In vivo protection against endotoxin by plasma high density lipoprotein. Proc. Natl. Acad. Sci. USA. 90: 12040-12044.
107. Hasty, A. H., M. F. Linton, S. J. Brandt, E. R. Babaev, L. A. Gleaves, and S. Fazio. 1999. Retroviral gene therapy in apoE-deficient mice: apoE expression in the artery wall reduces early foam cell lesion formation. Circulation. 99: 2571-2576.
108. Curtiss, L. K., and W. A. Boisvert. 2000. Apolipoprotein E and atherosclerosis. Curr. Opin. Lipidol. 11: 243-251.
109. Shimano, H., J. Ohsuga, M. Shimada, Y. Namba, T. Gotoda, K. Harada, M. Katsuki, Y. Yazaki, and N. Yamada. 1995. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall. J. Clin. Invest. 95: 469-476.
110. Bellosta, S., R. W. Mahley, D. A. Sanan, J. Murata, D. L. Newland, J. M. Taylor, and R. E. Pitas. 1995. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J. Clin. Invest. 96: 2170-2179.
111. Baitsch, D., H. H. Bock, T. Engel, R. Telgmann, C. Muller-Tidow, G. Varga, M. Bot, J. Herz, H. Robenek, A. von Eckardstein, et al. 2011. Apolipoprotein E induces anti-inflammatory phenotype in macrophages. Arterioscler. Thromb. Vasc. Biol. 31: 1160-1168.
112. Fazio, S., V. R. Babaev, A. B. Murray, A. H. Hasty, K. J. Carter, L. A. Gleaves, J. B. Atkinson, and M. F. Linton. 1997. Increased atherosclerosis in C57BL/6 mice reconstituted with apolipoprotein E null macrophages. Proc. Natl. Acad. Sci. USA. 94: 4647-4652.
113. -/-mice during disease regression. J. Clin. Invest. 121: 2025-2036.
114. Hoekstra, M., V. Frodermann, T. van den Aardweg, R. J. van der Sluis, and J. Kuiper. 2013. Leukocytosis and enhanced susceptibility to endotoxemia but not atherosclerosis in adrenalectomized apoE knockout mice. PLoS ONE. 8: e80441.
115. Murphy, A. J., M. Akhtari, S. Tolani, T. Pagler, N. Bijl, C. L. Kuo, M. Wang, M. Sanson, S. Abramowicz, C. Welch, et al. 2011. ApoE regulates hematopoietic stem cell proliferation, monocytosis, and monocyte accumulation in atherosclerotic lesions in mice. J. Clin. Invest. 121: 4138-4149.
116. Tolani, S., T. A. Pagler, A. J. Murphy, A. E. Bochem, S. Abramowicz, C. Welch, P. R. Nagareddy, S. Holleran, G. K. Hovingh, J. A. Kuivenhoven, et al. 2013. Hypercholesterolemia and reduced HDL-C promote hematopoietic stem cell proliferation and monocytosis: studies in mice and FH children. Atherosclerosis. 229: 79-85.
117. Tall, A. R., L. Yvan-Charvet, M. Westerterp, and A. J. Murphy. 2012. Cholesterol efflux a novel regulator of myelopoiesis and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 32: 2547-2552.
118. Murphy, A. J., M. Westerterp, L. Yvan-Charvet, and A. R. Tall. 2012. Anti-atherogenic mechanisms of high density lipoprotein: effects on myeloid cells. Biochim. Biophys. Acta. 1821: 513-521.
119. Brown, M. S., and J. L. Goldstein. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science. 232: 34-47.
120. Mahley, R. W., and Z. S. Ji. 1999. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40: 1-16.
121. Sharifov, O. F., G. Nayyar, D. W. Garber, S. P. Handattu, V. K. Mishra, D. Goldberg, G. M. Anantharamaiah, and H. Gupta. 2011. Apolipoprotein E mimetics and cholesterol-lowering properties. Am. J. Cardiovasc. Drugs. 11: 371-381.
122. Datta, G., D. W. Garber, B. H. Chung, M. Chaddha, N. Dashti, W. A. Bradley, S. H. Gianturco, and G. M. Anantharamaiah. 2001. Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J. Lipid Res. 42: 959-966.
123. Dyer, C. A., D. P. Cistola, G. C. Parry, and L. K. Curtiss. 1995. Structural features of synthetic peptides of apolipoprotein E that bind the LDL receptor. J. Lipid Res. 36: 80-88.
124. Clay, M. A., G. M. Anantharamaiah, M. J. Mistry, A. Balasubramaniam, and J. A. Harmony. 1995. Localization of a domain in apolipoprotein E with both cytostatic and cytotoxic activity. Biochemistry. 34: 11142-11151.
125. Nikoulin, I. R., and L. K. Curtiss. 1998. An apolipoprotein E synthetic peptide targets to lipoproteins in plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-rich lipoproteins in vivo. J. Clin. Invest. 101: 223-234.
126. Vedhachalam, C., V. Narayanaswami, N. Neto, T. M. Forte, M. C. Phillips, S. Lund-Katz, and J. K. Bielicki. 2007. The C-terminal lipid-binding domain of apolipoprotein E is a highly efficient mediator of ABCA1-dependent cholesterol efflux that promotes the assembly of high-density lipoproteins. Biochemistry. 46: 2583-2593.
127. Zheng, Y., A. B. Patel, V. Narayanaswami, G. L. Hura, B. Hang, and J. K. Bielicki. 2011. HDL mimetic peptide ATI-5261 forms an oligomeric assembly in solution that dissociates to monomers upon dilution. Biochemistry. 50: 4068-4076.
128. Li, F. Q., G. D. Sempowski, S. E. McKenna, D. T. Laskowitz, C. A. Colton, and M. P. Vitek. 2006. Apolipoprotein E-derived peptides ameliorate clinical disability and inflammatory infiltrates into the spinal cord in a murine model of multiple sclerosis. J. Pharmacol. Exp. Ther. 318: 956-965.
129. Laskowitz, D. T., S. E. Mckenna, P. Song, H. Wang, L. Durham, N. Yeung, D. Christensen, and M. P. Vitek. 2007. COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. J. Neurotrauma. 24: 1093-1107.
130. Sheng, Z., M. Prorok, B. E. Brown, and F. J. Castellino. 2008. N-methyl-D-aspartate receptor inhibition by an apolipoprotein E-derived peptide relies on low-density lipoprotein receptor-associated protein. Neuropharmacology. 55: 204-214.
131. 2: implications in the inhibition of atherosclerosis. Atherosclerosis. 208: 134-141.
132. Gupta, H., C. R. White, S. Handattu, D. W. Garber, G. Datta, M. Chaddha, L. Dai, S. H. Gianturco, W. A. Bradley, and G. M. Anantharamaiah. 2005. An apolipoprotein E mimetic peptide dramatically lowers atherogenic lipoproteins and restores endothelial function in Watanabe heritable hyperlipidemic rabbits. Circulation. 111: 3112-3118.
133. Handattu, S. P., G. Nayyar, D. W. Garber, M. N. Palgunachari, C. E. Monroe, T. D. Keenum, V. K. Mishra, G. Datta, and G. M. Anantharamaiah. 2013. Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice. Atherosclerosis. 227: 58-64.
134. Garber, D. W., S. Handattu, I. Aslan, G. Datta, M. Chaddha, and G. M. Anantharamaiah. 2003. Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis. 168: 229-237.
135. Goldberg, D. I., G. Nayyar, D. W. Garber, S. P. Handattu, and G. M. Anatharamaiah. 2013. Sustained effects of apolipoprotein E mimetic peptides on established atherosclerotic lesions in apo E null mice. Circulation. 128: A10759.
136. Datta, G., M. Chaddha, S. P. Handattu, M. N. Palgunachari, G. Nayyar, D. W. Garber, H. Gupta, C. R. White, and G. M. Anantharamaiah. 2010. ApoE mimetic peptide reduces plasma lipid hydroperoxide content with a concomitant increase in HDL paraoxonase activity. Adv. Exp. Med. Biol. 660: 1-4.
137. Handattu, S. P., C. E. Monroe, G. Nayyar, M. N. Palgunachari, I. Kadish, T. van Groen, G. M. Anantharamaiah, and D. W. Garber. 2013. In vivo and in vitro effects of an apolipoprotein E mimetic peptide on amyloid-β pathology. J. Alzheimers Dis. 36: 335-347.
138. Raffai, R. L., S. M. Loeb, and K. H. Weisgraber. 2005. Apolipoprotein E promotes the regression of atherosclerosis independently of lowering plasma cholesterol levels. Arterioscler. Thromb. Vasc. Biol. 25: 436-441.
139. Kothapalli, D., S. L. Liu, Y. H. Bae, J. Monslow, T. Xu, E. A. Hawthome, F. J. Byfield, P. Castagnini, S. Rao, D. J. Radar, et al. 2012. Cardiovascular protection by ApoE and ApoE-HDL linked to suppression of ECM gene expression and arterial stiffening. Cell Reports. 2: 1259-1271.
140. Swertfeger, D. K., and D. Y. Hui. 2001. Apolipoprotein E: A cholesterol transport protein with lipid transport-independent cell signaling properties. Front. Biosci. 6: D526-D535.
141. Nayyar, G., D. W. Garber, M. N. Palgunachari, C. E. Monroe, T. D. Keenum, S. P. Handattu, V. K. Mishra, and G. M. Anantharamaiah. 2012. Apolipoprotein E mimetic is more effective than apolipoprotein A-I mimetic in reducing lesion formation in older female apo E null mice. Atherosclerosis. 224: 326-331.
142. Sharifov, O. F., G. Nayyar, V. V. Ternovoy, M. N. Palgunachari, D. W. Garber, G. Anantharamaiah, and H. Gupta. Comparison of anti-endotoxin activity of apoE and apoA mimetic derivatives of a model amphipathic peptide 18A. Innate Immun. Epub ahead of print. Dec 9, 2013; doi:10.1177/1753425913514621.
143. Tytler, E. M., J. P. Segrest, R. M. Epand, S. Q. Nie, R. F. Epand, V. K. Mishra, Y. V. Venkatachalapathi, and G. M. Anantharamaiah. 1993. Reciprocal effects of apolipoprotein and lytic peptide analogs on membranes. Cross-sectional molecular shapes of amphipathic alpha-helixes control membrane stability. J. Biol. Chem. 268: 22112-22118.
144. Handattu, S. P., G. Datta, R. M. Epand, R. F. Epand, M. N. Palgunachari, V. K. Mishra, C. E. Monroe, T. D. Keenum, M. Chaddha, G. M. Anantharamaiah, et al. 2010. Oral administration of L-mR18L, a single domain cationic amphipathic helical peptide, inhibits lesion formation in ApoE null mice. J. Lipid Res. 51: 3491-3499.
145. Wool, G., C. A. Reardon, and G. S. Getz. Mimetic peptides of human apoA-I helix 10 get together to lower lipids and ameliorate atherosclerosis: is the action in the gut? J. Lipid Res. Epub ahead of print. August 1, 2014; doi:10.1194/jlr.E053538.
146. Dong, B., M. Wu, H. Li, F. B. Kraemer, K. Adeli, N. G. Seidah, S. Wook Park, and J. Liu. 2010. Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J. Lipid Res. 51: 1486-1495.
147. Antonopoulos, A. S., M. Margaritis, R. Lee, K. Channon, and C. Antoniades. 2012. Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. Curr. Pharm. Des. 18: 1519-1530.
148. Stein, E. A., S. Mellis, G. D. Yancopoulos, N. Stahl, D. Logan, W. B. Smith, E. Lisbon, M. Gutierrez, C. Webb, R. Wu, et al. 2012. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N. Engl. J. Med. 366: 1108-1118.
149. Farnier, M. 2013. PCSK9 inhibitors. Curr. Opin. Lipidol. 24: 251-258.
150. Raal, F. J., R. P. Giugliano, M. S. Sabatine, M. J. Koren, G. Langslet, H. Bays, D. Blom, M. Eriksson, R. Dent, S. M. Wasserman, et al. 2014. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. J. Am. Coll. Cardiol. 63: 1278-1288.
151. Stein, E. A., N. Honarpour, S. M. Wasserman, F. Xu, R. Scott, and F. J. Raal. 2013. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 128: 2113-2120.
152. Hemphill, L. C. 2010. Familial hypercholesterolemia: Current treatment options and patient selection for low-density lipoprotein apheresis. J. Clin. Lipidol. 4: 346-349.
153. Raal, F. J., and R. D. Santos. 2012. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 223: 262-268.
154. Fotakis, P., A. Vezeridis, I. Dafnis, A. Chroni, D. Kardassis, and V. I. Zannis. 2014. apoE3[K146N/R147W] acts as a dominant negative apoE form that prevents remnant clearance and inhibits the biogenesis of HDL. J. Lipid Res. 55: 1310-1323.